Molecular Mechanisms of Immunomodulation Properties of Mesenchymal Stromal Cells: A New Insight into the Role of ICAM-1

Stem Cells International

Volumn 2017, Issue , 2017, Pages

  Rubtsov, Yury ^a   Goryunov, Krill ^a   Romanov, Rondrey ^a   Suzdaltseva, Yulia ^b   Sharonov, George ^a   Tkachuk, Vsevolod ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA;

ADIPOSE DERIVED STEM CELL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MOLECULAR DYNAMICS; T LYMPHOCYTE; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 85027026738     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2017/6516854     Document Type: Article

References (41)

1. A. J. Friedenstein, R. K. Chailakhjan, and K. S. Lalykina, "The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells," Cell Tissue Kinetics, vol. 20, no. 3, pp. 393-403, 1970.
2. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
3. D. J. Prockop, "Marrow stromal cells as stem cells for nonhematopoietic tissues," Science, vol. 276, no. 5309, pp. 71-74, 1997.
4. H. K. Salem and C. Thiemermann, "Mesenchymal stromal cells: current understanding and clinical status," Stem Cells, vol. 28, no. 3, pp. 585-596, 2010.
5. E. H. Javazon, K. J. Beggs, and A. W. Flake, "Mesenchymal stem cells: paradoxes of passaging," Experimental Hematology, vol. 32, no. 5, pp. 414-425, 2004.
6. R. J. Deans and A. B. Moseley, "Mesenchymal stem cells: biology and potential clinical uses," Experimental Hematology, vol. 28, no. 8, pp. 875-884, 2000.
7. N. I. Kalinina, V. Y. Sysoeva, K. A. Rubina, Y. V. Parfenova, and V. A. Tkachuk, "Mesenchymal stem cells in tissue growth and repair," Acta Naturae, vol. 3, no. 4, pp. 30-37, 2011.
8. A. Bartholomew, C. Sturgeon, M. Siatskas et al., "Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo," Experimental Hematology, vol. 30, no. 1, pp. 42-48, 2002.
9. Y. P. Rubtsov, Y. G. Suzdaltseva, K. V. Goryunov, N. I. Kalinina, V. Y. Sysoeva, and V. A. Tkachuk, "Regulation of immunity via multipotent mesenchymal stromal cells," Acta Naturae, vol. 4, no. 1, pp. 23-31, 2012.
10. O. DelaRosa, E. Lombardo, A. Beraza et al., "Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells," Tisssue Engeneering Part A, vol. 15, no. 10, pp. 2795-2807, 2009.
11. I. Rasmusson, "Immune modulation by mesenchymal stem cells," Experimental Cell Research, vol. 312, no. 12, pp. 2169-2179, 2006.
12. M. W. Taylor and G. S. Feng, "Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism," FASEB Journal, vol. 5, no. 11, pp. 2516-2522, 1991.
13. X. Hui, G. X. Zhang, B. Ciric, and A. Rostami, "IDO: a doubleedged sword for TH1/TH2 regulation," Immunology Letters, vol. 121, no. 1, pp. 1-6, 2008.
14. G. Frumento, R. Rotondo, M. Tonetti, and G. B. Ferrara, "T cell proliferation is blocked by indoleamine-2,3-dioxygenase," Transplantation Proceedings, vol. 33, no. 1-2, pp. 428-430, 2001.
15. G. Ren, J. Su, L. Zhang et al., "Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression," Stem Cells, vol. 27, no. 8, pp. 1954-1962, 2009.
16. C. Bogdan, "Nitric oxide and the immune response," Nature Immunology, vol. 2, no. 10, pp. 907-916, 2001.
17. G. Ren, L. Zhang, X. Zhao et al., "Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide," Cell Stem Cell, vol. 2, no. 2, pp. 141-150, 2008.
18. K. Sato, K. Ozaki, I. Oh et al., "Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells," Blood, vol. 109, no. 1, pp. 228-234, 2007.
19. M. Krampera, S. Glennie, J. Dyson et al., "Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide," Blood, vol. 101, no. 9, pp. 3722-3729, 2003.
20. M. Di Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli," Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
21. R. E. Newman, D. Yoo, M. A. LeRoux, and A. Danilkovitch-Miagkova, "Treatment of inflammatory diseases with mesenchymal stem cells," Inflammation & Allergy-Drug Targets, vol. 8, no. 2, pp. 110-123, 2009.
22. A. Augello, R. Tasso, S. M. Negrini et al., "Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway," European Journal of Immunology, vol. 35, no. 5, pp. 1482-1490, 2005.
23. Q. Xue, X. Y. Luan, Y. Z. Gu et al., "The negative cosignaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity," Stem Cells Development, vol. 19, no. 1, pp. 27-38, 2010.
24. G. Ren, X. Zhao, L. Zhang et al., "Inflammatory cytokineinduced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression," The Journal of Immunology, vol. 184, no. 5, pp. 2321-2328, 2010.
25. Y. Shi, J. Su, A. I. Roberts, P. Shou, A. B. Rabson, and G. Ren, "How mesenchymal stem cells interact with tissue immune responses," Trends in Immunology, vol. 33, no. 3, pp. 136-143, 2012.
26. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses," Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
27. Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications," Nature Immunology, vol. 15, no. 11, pp. 1009-1016, 2014.
28. K. English, "Mechanisms of mesenchymal stromal cell immunomodulation," Immunology and Cell Biology, vol. 91, no. 1, pp. 19-26, 2013.
29. P. A. Zuk, M. Zhu, H. Mizuno et al., "Multilineage cells from human adipose tissue: implications for cell-based therapies," Tissue Engineering, vol. 7, no. 2, pp. 211-228, 2001.
30. C. P. Corkum, D. P. Ings, C. Burgess, S. Karwowska, W. Kroll, and T. I. Michalak, "Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT) and standard density gradient," BMC Immunology, vol. 16, no. 48, pp. 2-18, 2015.
31. O. Boyman and J. Sprent, "The role of interleukin-2 during homeostasis and activation of the immune system," Nature Reviews Immunology, vol. 12, no. 3, pp. 180-190, 2012.
32. R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation," Blood, vol. 103, no. 12, pp. 4619-4622, 2004.
33. K. English, F. P. Barry, C. P. Field-Corbett, and B. P. Mahon, "IFN-? and TNF-? differentially regulate immunomodulation by murine mesenchymal stem cells," Immunology Letters, vol. 110, no. 2, pp. 91-100, 2007.
34. R. Maccario, M. Podesta, A. Moretta et al., "Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype," Haematologica, vol. 90, no. 4, pp. 516-525, 2005.
35. J. D. Glenn and K. A. Whartenby, "Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy," World Journal of Stem Cells, vol. 6, no. 5, pp. 526-539, 2014.
36. Y. Shi, G. Hu, J. Su et al., "Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair," Cell Research, vol. 20, no. 5, pp. 510-518, 2010.
37. M. E. Groh, B. Maitra, E. Szekely, and O. N. Koç, "Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells," Experimental Hematology, vol. 33, no. 8, pp. 928-934, 2005.
38. H. Mohammadpour, A. A. Pourfathollah, M. N. Zarif, and M. T. Tahoori, "TNF-? modulates the immunosuppressive effects of MSCs on dendritic cells and T cells," International Immunopharmacology, vol. 28, no. 2, pp. 1009-1017, 2015.
39. E. Zappia, S. Casazza, E. Pedemonte et al., "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy," Blood, vol. 106, no. 5, pp. 1755-1761, 2005.
40. K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon, "Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells," British Society for Immunology, Clinical and Experimental Immunology, vol. 156, no. 1, pp. 149-160, 2009.
41. M. K. Majumdar, M. Keane-Moore, D. Buyaner et al., "Characterization and functionality of cell surface molecules on human mesenchymal stem cells," Journal of Biomedical Science, vol. 10, no. 2, pp. 228-241, 2003.